Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haige Ye

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Translational Medicine|June 26, 2020
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy targetBin Zhou, Xianghong Jin, Weiwei Jin, et al.
Acta Biomaterialia|April 11, 2022
Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membraneBin Liang, Dawei Jiang, Luqi Pan, et al.
American Journal of Clinical Oncology|February 9, 2018
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma)Dongfeng Zeng, Aakash Desai, Fangfang Yan, et al.
Therapeutic Advances in Hematology|January 30, 2026
The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphomaSiqian Wang, Xi Xu, Yongyong Ma, et al.
Clinical Therapeutics|August 8, 2025
Pegylated Liposomal Doxorubicin Confers a High Risk for Pneumocystis Jirovecii Pneumonia in Patients With Diffuse Large B-Cell LymphomaSiqian Wang, Xi Xu, Yongyong Ma, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 15, 2018
Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapyHaige Ye, Aakash Desai, Shengjian Huang, et al.
Scientific Reports|March 14, 2025
POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphomaYizi He, Caiqin Wang, Tao Pan, et al.
Hematological Oncology|April 27, 2024
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphomaJiangfang Feng, Yue Fei, Meng Gao, et al.
Clinical Epigenetics|February 5, 2025
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world settingYilan Xu, Danyang Li, Na Wang, et al.
Frontiers in Pharmacology|December 31, 2024
Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in ChinaRongqi Li, Yuhan Zeng, Yizhang Chen, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Translational Medicine|June 26, 2020
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy targetBin Zhou, Xianghong Jin, Weiwei Jin, et al.
Acta Biomaterialia|April 11, 2022
Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membraneBin Liang, Dawei Jiang, Luqi Pan, et al.
American Journal of Clinical Oncology|February 9, 2018
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma)Dongfeng Zeng, Aakash Desai, Fangfang Yan, et al.
Therapeutic Advances in Hematology|January 30, 2026
The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphomaSiqian Wang, Xi Xu, Yongyong Ma, et al.
Clinical Therapeutics|August 8, 2025
Pegylated Liposomal Doxorubicin Confers a High Risk for Pneumocystis Jirovecii Pneumonia in Patients With Diffuse Large B-Cell LymphomaSiqian Wang, Xi Xu, Yongyong Ma, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 15, 2018
Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapyHaige Ye, Aakash Desai, Shengjian Huang, et al.
Scientific Reports|March 14, 2025
POD24-Based prognostic signature enables personalized risk stratification in mantle cell lymphomaYizi He, Caiqin Wang, Tao Pan, et al.
Hematological Oncology|April 27, 2024
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphomaJiangfang Feng, Yue Fei, Meng Gao, et al.
Clinical Epigenetics|February 5, 2025
miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world settingYilan Xu, Danyang Li, Na Wang, et al.
Frontiers in Pharmacology|December 31, 2024
Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in ChinaRongqi Li, Yuhan Zeng, Yizhang Chen, et al.
Pageof 5